Jacobio’s KRAS G12C Inhibitor Glecirasib Gains Approval for Market Launch

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has provided an update.

Jacobio Pharmaceuticals has received approval from China’s National Medical Products Administration for its KRAS G12C inhibitor, glecirasib, to be launched for patients with non-small cell lung cancer harboring KRAS G12C mutations. This approval, based on a pivotal Phase II clinical trial, triggers a milestone payment from partner Shanghai Allist Pharmaceuticals. The trial demonstrated significant efficacy and a favorable safety profile for glecirasib, marking a strategic advancement for Jacobio in the oncology market.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$3.70 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. is a company dedicated to developing innovative products and solutions aimed at improving patient health. The company’s research and development pipeline focuses on novel molecular targets across six major signaling pathways, including KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. Jacobio aspires to be a global leader in drug research and development, with R&D centers located in Beijing, Shanghai, and Boston.

Average Trading Volume: 8,912,683

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.65B

Learn more about 1167 stock on TipRanks’ Stock Analysis page.